High
3.205
Open
3.180
VWAP
3.16
Vol
594.17K
Mkt Cap
439.74M
Low
3.110
Amount
1.87M
EV/EBITDA(TTM)
--
Total Shares
137.59M
EV
327.10M
EV/OCF(TTM)
--
P/S(TTM)
--
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Show More
6 Analyst Rating

315.09% Upside
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 13.20 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy

315.09% Upside
Current: 3.180

Low
9.00
Averages
13.20
High
24.00

315.09% Upside
Current: 3.180

Low
9.00
Averages
13.20
High
24.00
Raymond James
Sean McCutcheon
Outperform
initiated
$9
2025-07-01
Reason
Raymond James
Sean McCutcheon
Price Target
$9
2025-07-01
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics with an Outperform rating and $9 price target. Tovecimig has demonstrated superiority on response rate to its comparator arm in the Phase 3 COMPANION-002 study, notes the analyst, who believes it will hit statistical significance on progression-free survival with a U.S. approval in second-line biliary tract cancer during 2026. Should Tovecimig get approved, the firm thinks the launch of the drug will be "strong given the low bar" and lack of efficacy for standard chemotherapy regimens in the roughly 60% of second-line BTC patients without targetable genomic alterations, the analyst added.
Guggenheim
Buy
downgrade
$12 -> $10
2025-05-09
Reason
Guggenheim
Price Target
$12 -> $10
2025-05-09
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Compass Therapeutics to $10 from $12 and keeps a Buy rating on the shares. After the quarterly report, the firm updated its model to account for Q1 results and refined launch timing assumptions for tovecimig, the analyst tells investors.
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
n/a
2025-04-22
Reason
Guggenheim
Michael Schmidt
Price Target
n/a
2025-04-22
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$32
2025-04-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$32
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$24
2025-04-21
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$24
2025-04-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$10 → $24
2025-04-04
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10 → $24
2025-04-04
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Compass Therapeutics Inc. (CMPX.O) is -6.22, compared to its 5-year average forward P/E of -6.13. For a more detailed relative valuation and DCF analysis to assess Compass Therapeutics Inc. 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-6.13
Current PE
-6.22
Overvalued PE
-3.46
Undervalued PE
-8.81
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.04
Current EV/EBITDA
-4.01
Overvalued EV/EBITDA
-0.46
Undervalued EV/EBITDA
-5.62
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
32.72
Current PS
0.00
Overvalued PS
145.95
Undervalued PS
-80.51
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+40.69%
-17.97M
Operating Profit
FY2025Q1
YoY :
+54.19%
-16.63M
Net Income after Tax
FY2025Q1
YoY :
+50.00%
-0.12
EPS - Diluted
FY2025Q1
YoY :
-4.77%
-13.23M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
11.4M
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
21.1K
USD
Months
3-6
2
59.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.0M
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
8.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
11.4M
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
21.1K
USD
Months
3-6
2
59.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CMPX News & Events
Events Timeline
2025-05-08 (ET)
2025-05-08
08:08:39
Compass Therapeutics has anticipated cash runway into 2027

2025-05-08
08:08:10
Compass Therapeutics reports Q1 EPS (12c), consensus (11c)

2025-04-28 (ET)
2025-04-28
08:08:23
Compass Therapeutics presents data on efficacy of CTX-471

Sign Up For More Events
Sign Up For More Events
News
4.0
07-01BenzingaRaymond James Reinstates Outperform on Compass Therapeutics, Announces $9 Price Target
9.0
04-21NewsfilterCompass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
4.0
04-04BenzingaHC Wainwright & Co. Maintains Buy on Compass Therapeutics, Raises Price Target to $24
Sign Up For More News
People Also Watch

QUAD
Quad/Graphics Inc
5.850
USD
+1.21%

VLN
Valens Semiconductor Ltd
3.120
USD
0.00%

RIGL
Rigel Pharmaceuticals Inc
20.170
USD
-1.27%

DADA
Dada Nexus Ltd
0
USD
-1.28%

SAR
Saratoga Investment Corp
25.190
USD
-0.59%

NECB
Northeast Community Bancorp Inc
22.500
USD
+0.90%

NPCE
Neuropace Inc
8.980
USD
-0.99%

RBB
RBB Bancorp
18.950
USD
-0.79%

TITN
Titan Machinery Inc
20.120
USD
+1.56%

RRBI
Red River Bancshares Inc
61.000
USD
+0.26%
FAQ

What is Compass Therapeutics Inc. (CMPX) stock price today?
The current price of CMPX is 3.18 USD — it has increased 0.63 % in the last trading day.

What is Compass Therapeutics Inc. (CMPX)'s business?

What is the price predicton of CMPX Stock?

What is Compass Therapeutics Inc. (CMPX)'s revenue for the last quarter?

What is Compass Therapeutics Inc. (CMPX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Compass Therapeutics Inc. (CMPX)'s fundamentals?

How many employees does Compass Therapeutics Inc. (CMPX). have?
